Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
HOME > ORGANIZATION
ORGANIZATION
- Keizai Doyukai Recommends Measures to Ensure Adequate Funding for Proposed Japanese NIH
October 31, 2013
- Generic Makers to Jointly Outsource GMP Inspections on Drug Substance Suppliers; Pilot to Begin by March
October 28, 2013
- Medwatcher Japan Calls for Legislation to Regulate Clinical Research in Wake of Diovan Scandal
October 28, 2013
- JPMA to Consider Information Disclosure on Provision of Labor to Research Institutes in Response to Diovan Scandal
October 28, 2013
- JMA Vice Pres. Nakagawa to Be Reinstated as CSIMC Member
October 25, 2013
- No Clear Violation of Fair Competition Code in Diovan Case: Maker FTC Exec
October 22, 2013
- JPMA Will Announce Response to Violation of PAL by Mitsubishi Tanabe in Near Future: Director General Goto
October 21, 2013
- Japan Self-Medication Industry’s Request Letter to Health Minister Factually Incorrect: JMA Exec
October 10, 2013
- Removal of JMA, JPA Members from OTC Drug Review Council, Open Discussion Would Be Difficult, Says JMA Exec
October 9, 2013
- Japan Self-Medication Industry Requests Health Minister to Remove JMA, JPA Members from OTC Drug Review Council
October 9, 2013
- Blanket 14-Day Prescription Limit Should Be Scrapped: EFPIA Japan Chair
October 8, 2013
- Diovan Issue is “Isolated Example,” Confidence in Japan Clinical Trials Not Lost: President Viehbacher of EFPIA
October 7, 2013
- JPMA Suspends Membership of Novartis Pharma in Response to Diovan Scandal
October 4, 2013
- JPMA Compliance Committee to Decide Penalties for Novartis for Diovan Case as Requested by Dr Teshirogi
October 3, 2013
- JGA Tells Members to Use Unified Trade Name “Losarhyd” for Generic Version of Combination Drug Preminent
October 1, 2013
- Generic Share Increases to 26.6% on Volume Basis in April-June 2013: JGA
October 1, 2013
- JSGM to Propose Incentive Dispensing Fee for Pharmacies That Carry Cheaper Generics, Unification of Premiums for Generic Dispensing Systems
September 26, 2013
- Japan, US Should Promote High Standards for Intellectual Property Protection and Pricing Transparency in TPP: PhRMA Executives
September 24, 2013
- JPMA Senior Managing Director Hiroaki Nakatani to Retire
September 17, 2013
- Transparency Guidelines: JPMA Says Requested Viewers’ Names, Affiliations Could Be Checked before Disclosing Individual Payment Information
September 13, 2013
ページ
The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…